<DOC>
	<DOCNO>NCT00586885</DOCNO>
	<brief_summary>Purpose study assess therapeutic efficacy L-alanine improve biological histological finding administrate 6-18g/day L-alanine one year . We also assess safety toxicity profile long-term administration L-alanine .</brief_summary>
	<brief_title>Effects Alanine Patients With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Males female , age 18 75 Histological diagnosis steatohepatitis without fibrosis make within one year entry Transaminase level ( ALT AST ) 1.5 time upper normal limit least two occasion one assessment three month prior treatment study Previous current alcohol consumption le 20g per day patientprovided information . Written inform consent specific protocol available prior entry . Patients diabetes stable medical management six month prior entry anticipate stable program throughout study eligible . Medications may use include insulin , biguanides sulfonylurea . Patients congestive heart failure , hypertension arrhythmia control medication without cardiac episode past 6 month eligible . Any cause liver disease nonalcoholic steatohepatitis confirm patient history , laboratory data , histological data Decompensated liver disease base laboratory data , clinical manifestation 1 . Hemoglobin &lt; 11.0g/dl male , &lt; 10.0 g/dl female 2 . White blood cell &lt; 2000 /mm3 3 . Platelet count &lt; 50,000/mm3 4 . Prothrombin time &gt; INR 1.5 5 . Total Bilirubin &gt; 2.0 g/dl 6 . Albumin &lt; 3.0/dl 7 . The presence ascites 8 . The presence bleeding varix 9 . The presence spontaneous encephalopathy Any previous experimental treatment NASH within past 3 month betaine , thiazolidinediones , Î±tocopherol , UDCA Preexisting diseases/situations could interfere result completion trial . Uncontrolled diabetes mellitus meeting follow criterion previous 3 month 1 . Fasting blood sugar &gt; 200 mg/dl 2 . Hemoglobin A1c &gt; 12 % Renal liver transplant patient Renal dysfunction previous 3 month ) CCr &lt; 50ml/min Severe cardiovascular dysfunction previous 6 month Congestive heart failure Uncontrolled hypertension Uncontrolled arrhythmia Patients hyperlipidemia medical program control lipids change drug treatment proceed six month anticipate change year study . Chronic pulmonary disease COPD require corticosteroid therapy previous 3 month Active autoimmune immunologically mediate disease include systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel diseases previous 12 month Previous ( three year ) present malignant disease except nonmelanoma skin cancer Untreated hyperthyroidism hypothyroidism Substance abuse oral , I.V. , inhale drug . If patient history substance abuse consider participant trial , patient must abstain use abused substance least one year . Patients receive methadone within past 6 month also exclude . Any condition would make patient unsuitable enrollment opinion investigator term interference complete trial and/or result trial . Pregnant woman Unwillingness patient /or partner use contraceptive treatment 3 month discontinuation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>L-Alanine</keyword>
</DOC>